Commentary: A push for drug price reform

A meeting between President Trump and the pharmaceutical industry was called off Tuesday in the wake of his newly signed executive orders on drug prices.

Trump signed four orders, including easing rules on drug imports from Canada and lowering the cost of insulin for some Americans.

In a new GHN Commentary, former health care executive Jack Bernard says the most significant order would start “what is called in the health care industry “most favored nations” pricing for Medicare Part B drugs.

“We should all support his efforts and ask that the initiative be expanded by Congress to cover all drugs bought by Americans. It makes absolutely no sense for U.S. citizens to pay excessively high pharmaceutical prices in order to support drug research that will benefit the entire world.’’

Here’s a link to his Commentary.